Evolving Treatment Paradigms for Bladder Cancer: Expert Perspectives on the Latest Data

Released On
July 19, 2022

Expires On
July 19, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology, Urology

Topic(s)
Bladder Cancer, Oncology

Scroll to the Bottom of this Information to Begin this Course

Provided by Creative Educational Concepts, LLC

This activity is supported through an independent educational grant from AstraZeneca.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Urologists and Urologic Oncologists.

Program Overview

Join key thought leaders in the world of bladder cancer – Drs. Sam Chang and Shilpa Gupta – as they review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy. Our experts will also provide the tools necessary for effective therapeutic sequencing of intravesical chemotherapy, BCG, platinum chemotherapy, ICIs, and surgical modalities, as well as adaptive integration of novel combinatorial regimens. Finally, the panel will offer expert insights for anticipating and managing immune-mediated adverse events (imAEs) in patients receiving ICIs.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Appraise the expanding clinical trial evidentiary base in NMIBC and MIBC, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment.
  • Examine the evolving bladder cancer management calculus in non-metastatic disease, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating intravesical chemotherapy, BCG, platinum chemotherapy, immune checkpoint inhibitors, and surgical modalities.
  • Design evidence-supported treatment plans for patients with bladder cancer, both in NMIBC and as neoadjuvant/adjuvant therapy in MIBC, by effectively integrating consensus guideline recommendations with patient-centric factors (i.e., performance status, renal function, PD-L1 expression, cytopathology, urinary markers, etc.).
  • Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors, either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.

Faculty

FACULTY_NAME

Sam S. Chang MD, MBA
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Chief, Division of Urologic Oncology
Vanderbilt Ingram Cancer Center
Nashville, TN

FACULTY_NAME

Shilpa Gupta, MD

Director of the Genitourinary Medical Oncology
Cleveland Clinic
Co-Leader of the Genitourinary Oncology Program
Taussig Cancer Institute
Cleveland, OH

 

Accreditation Statement

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

CEC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Disclosures of Conflicts of Interest

Planners and Faculty
Sam S. Chang, MD, MBA-has disclosed he is a consultant for Janssen, MIR, Pacific Edge, Merck, Pfizer, Prokarium, Photocuret, Urigen, and UroToday.

Shilpa Gupta, MD-has disclosed she is a member of the Speakers' Bureau for BMS, Gilead, SeaGen, and Janssen. She is a consultant for BMS, EMD Serono, Loxo Oncology, Merck, Natera, Pfizer, and SeaGen. She also has equity in Biontek and Moderna.

Reviewer
Bashir Al Hussein, MD-has disclosed he has no financial disclosures in relation to this activity.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

CEC requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: lillya@ceconcepts.com